Background Antithrombotic therapy, including direct oral anticoagulants, is recommended in
patients with non-valvular atrial fibrillation (NVAF) who are at intermediate-to-high risk of …

Background In “real-world” practice, anticoagulant therapy is indicated for patients whose
clinical profiles are not addressed in randomized clinical trials. We assessed the …

Background The recent availability of dabigatran, a novel oral anticoagulant, provided a new
treatment option for stroke prevention in atrial fibrillation beyond warfarin, the main therapy …

Background Oral anticoagulants use has increased rapidly, internationally. Here we look at
risks and benefits, based on Japanese data, of therapy with low risk non-valvular atrial …

Dabigatran is approved for stroke risk reduction in patients with nonvalvular atrial fibrillation
(NVAF). Data from diverse clinical practice settings will help establish whether the risk …

Background and Purpose—Whether dabigatran is associated with different risks of
cardiovascular, bleeding events, and mortality from warfarin in Asian patients with …

Background Dabigatran is one of the three newer oral anticoagulants (OACs) recently
approved in the United States for stroke prevention in non-valvular atrial fibrillation (NVAF) …

BACKGROUND Most of the randomized clinical trials that led to the wide use of non-vitamin
K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation (AF) …

Background: Dabigatran is a kind of oral anticoagulant and there was little review only about
dabigatran and warfarin used in patients with atrial fibrillation. This meta-analysis only …

Objectives: There is scarce evidence comparing novel oral anticoagulants (NOACs) with
warfarin in real-world settings in Japan. This study compared the risk of bleeding events …